Patent ID: 8173601

Claim:
A method for reducing myeloma tumor cell burden in a human patient, the method comprising administering to a patient afflicted with multiple myeloma an effective amount of an activin type IIa receptor-immunoglobulin Fc domain (ActRIIa-Fc) fusion protein to reduce myeloma tumor cell burden in the patient, wherein the ActRIIA-Fc fusion protein is selected from the group consisting of: a) a dimer formed of two polypeptides that each comprise an amino acid sequence at least 95% identical to SEQ ID NO:2 joined by disulfide bonding; b) a dimer formed of two polypeptides that each comprise an amino acid sequence at least 95% identical to SEQ ID NO:3 joined by disulfide bonding; c) a dimer formed of two polypeptides that each comprise an amino acid sequence at least 95% identical to SEQ ID NO:7 joined by disulfide bonding; and d) a dimer formed of two polypeptides that each comprise an amino acid sequence at least 95% identical to SEQ ID NO:12 joined by disulfide bonding, wherein the ActRIIa-Fc fusion protein comprises three or more sialic acid moieties, and wherein the ActRIIa-Fc fusion protein binds to activin A.